The prolonged slump in IPO of pharmaceutical bio

Wonteg·RP BIO can be listed in Q2

Popular stocks disappear due to weak bio investor sentiment

Amid the prolonged sluggish trend in the IPO market in the pharmaceutical bio industry, attention is being paid to whether newly challenged companies will be able to draw a turnaround.

 

According to the pharmaceutical industry on the 19th, there are two pharmaceutical bio companies that have been listed in the second quarter of this year, Wonteg and RP BIO.

 

On top of that, Immunemed, Lunit, and Shaperon have proposed listing on KOSDAQ within the first half of the year.

 

However, they have not yet been approved for a preliminary screening of the listing.

 

RP BIO passed a preliminary review for listing on KOSDAQ on the 14th.

 

It has been about four months since it filed a preliminary review in December last year.

 

RP BIO is a manufacturer of soft capsule-type medicines and health functional foods.

 

Its sales and operating profit last year were 114.9 billion won and 5.8 billion won.

 

The largest shareholder is Yoon Jae-hoon, the second son of honorary chairman Yoon Young-hwan, founder of Daewoong Pharmaceutical.

 

Prior to this, On the 31st of last month, Wonteg received approval for a preliminary review.

 

It submitted a securities report on the 1st of this month.

 

Wonteg is pushing for listing on KOSDAQ through a merger and acquisition of SPAC.

 

Wonteg is a company that manufactures and sells laser and ultrasound medical devices related to skin beauty.

 

On the 25th, Wonteg is raising the mood by announcing IR events related to listing.

 

The pharmaceutical bio industry is paying attention to whether the two companies will be successful in IPO.

 

Given that the IPO of pharmaceutical bio companies failed to make a hit in the first quarter, attention is growing on whether it will continue its sluggish trend in the second quarter or succeed in reversing the atmosphere.

 

Three pharmaceutical bio companies listed this year are said to have failed to make a hit.

 

Ad Biotech, which was listed in January, and Noul, which was listed in March, were decided to have a lower public offering price than Hope Band.

 

BiofDNC, which was listed in February, has remained lower than the public offering price until recently after its stock price plunged on the first day of listing.

 

As the pharmaceutical bio IPO market shrinks, more and more companies are giving up listing in the middle.

 

In March, Boronoi submitted a report to the Financial Supervisory Service to withdraw its listing.

 

Boronoi even received approval for listing, but temporarily suspended its listing plan as it failed to predict demand.

 

KMRI, Finemedix, and FutureMedicine also voluntarily withdrew at the preliminary screening stage for listing.

 

In the first half of last year alone, eight companies were newly and previously listed through corporate disclosure.

 

Starting with PBPharma, Prestige Biologics, NeoImuneTech, Biodyne, SK Bioscience, HPO, GeneSystem, and ADM Korea debuted.

 

Most of them were successful in box office.

 

SK Bioscience succeeded in publicizing 1.4918 trillion won when it was listed on the securities market in March last year.

 

Institutional investment conducted prior to listing recorded a competition ratio of 1275.47 to 1.

 

In the subscription for general investors, more than 63 trillion won of evidence was collected.

 

The industry believes that the sluggish IPO market has been affected by a combination of rising U.S.

 

interest rates, the sluggish domestic stock market atmosphere due to the Ukrainian war, and weak investor sentiment in the bio industry.

 

Another reason is that there are no large pharmaceutical bio companies that are about to be listed.

 

This is in contrast to the consecutive listing of large pharmaceutical bio companies such as SK Biopharm two years ago and SD BioSensor, Inc·HK inno.N last year.